Q-omics provides the consensus-scored ITGA8 profile across patient tissues and cancer cell-line models. ITGA8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ITGA8 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, ITGA8 RNA expression shows 23,028 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BLCA, and LSCC as cancer lineages where ITGA8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITGA8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITGA8 survival associations across molecular data types. ITGA8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITGA8 RNA expression–survival associations across cancer types. High ITGA8 expression shows unfavorable associations in KIRP, but favorable associations in KIRC, HNSC, LUAD, SKCM and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ITGA8 RNA expression.
This table summarizes ITGA8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ITGA8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITGA8 shows lower tumor expression in BLCA, LUAD, KICH, COAD, THCA and LUSC. The BLCA box plot shows higher ITGA8 RNA expression in normal versus tumor tissue (log2 FC = −3.553, t-test p < 0.001).
This table shows molecular features associated with ITGA8 in patient tissues and cancer cell lines. In patient samples, ITGA8 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ITGA8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
